Alphatec Holdings, Inc. (ATEC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alphatec Holdings, Inc. (ATEC) trades at $9.30 with AI Score 17/100 (Grade F). Alphatec Holdings, Inc. focuses on designing, developing, and marketing technologies for spinal surgery. Market cap: $1.43B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026ATEC stock analysis for 2026: Analysts have set a consensus price target of $25.00 for Alphatec Holdings, Inc., suggesting 168.7% upside from the current price of $9.30. The AI MoonshotScore is 17/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ATEC: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Alphatec Holdings, Inc. (ATEC) Healthcare & Pipeline Overview
Alphatec Holdings, Inc. (ATEC) is a medical technology company specializing in innovative solutions for spinal disorders, including advanced surgical systems and biologics. ATEC's focus on neural safety and minimally invasive techniques positions it within the competitive medical device landscape, serving a growing market for spinal treatments.
What Is the Investment Thesis for ATEC?
Alphatec Holdings, Inc. presents a compelling investment thesis centered on its innovative product portfolio and strategic focus on the spinal surgery market. With a market capitalization of $1.43B, ATEC is positioned to capitalize on the increasing demand for advanced spinal treatments. The company's SafeOp Neural InformatiX System and Sigma series of access systems offer unique value propositions by reducing nerve injury risks and improving surgical precision. Key growth catalysts include the continued adoption of ATEC's minimally invasive surgical solutions and the expansion of its biologics offerings. The company's gross margin of 65.3% indicates strong pricing power and efficient operations. However, the negative profit margin of -15.9% highlights the need for improved cost management and increased sales volume to achieve profitability. The company's beta of 1.04 suggests a market correlation. Investors should monitor ATEC's ability to drive revenue growth, manage expenses, and navigate the competitive landscape to realize its full potential.
Based on FMP financials and quantitative analysis
ATEC Key Highlights
- Market capitalization of $1.43B, reflecting investor confidence in Alphatec's growth potential.
- Gross margin of 65.3%, indicating strong pricing power and efficient cost management in product sales.
- Offers SafeOp Neural InformatiX System, a key differentiator designed to reduce the risk of intraoperative nerve injury.
- Comprehensive product portfolio includes spinal fixation systems, interbody implants, and biologics, addressing a wide range of spinal disorders.
- Distribution network through independent distributors and direct sales representatives in the United States, ensuring broad market access.
Who Are ATEC's Competitors?
ATEC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CDTX Cidara Therapeutics, Inc. | $221.38 | +0.00% | $5.61B | 46 |
| SRRK Scholar Rock Holding Corporation | $55.03 | +0.27% | $6.59B | 45 |
| LEGN Legend Biotech Corporation | $27.97 | -6.49% | $5.17B | 32 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATEC's Key Strengths?
- Innovative product portfolio with proprietary technologies like SafeOp.
- Comprehensive range of spinal fixation systems, interbody implants, and biologics.
- Established distribution network in the United States.
- Strong focus on research and development.
What Are ATEC's Weaknesses?
- Negative profit margin (-15.9%) indicating profitability challenges.
- Reliance on independent distributors for sales and marketing.
- Limited geographic presence outside the United States.
- High competition in the medical device industry.
What Could Drive ATEC Stock Higher?
- Launch of new spinal fixation systems and interbody implants in Q3 2026, expanding the product portfolio.
- Continued adoption of the SafeOp Neural InformatiX System, driving revenue growth and market share.
- Expansion of biologics offerings through research and development, enhancing surgical outcomes.
What Are the Key Risks for ATEC?
- Financial-distress signal — its Altman Z-Score of -0.54 sits in the distress zone (elevated bankruptcy risk).
- Product liability lawsuits related to spinal surgery devices, impacting financial performance and reputation.
- Regulatory changes affecting the approval and marketing of medical devices, increasing compliance costs.
- Intense competition from established medical device companies, limiting market share and pricing power.
What Are the Growth Opportunities for ATEC?
- Expansion of Minimally Invasive Surgery (MIS) Solutions: The market for minimally invasive spinal surgery is growing due to reduced recovery times and improved patient outcomes. Alphatec's Invictus MIS SingleStep System and squadron lateral retractor are well-positioned to capitalize on this trend. By investing in R&D and surgeon training programs, Alphatec can increase adoption of its MIS solutions, targeting a market estimated to reach $3.5 billion by 2028.
- Strategic Partnerships and Acquisitions: Forming strategic alliances with hospitals, research institutions, and other medical device companies can accelerate product development and market penetration. Acquiring complementary technologies or companies can expand Alphatec's product portfolio and geographic reach. This approach can drive revenue growth and enhance the company's competitive position, potentially adding $50-100 million in revenue within the next 3-5 years.
- Geographic Expansion: While Alphatec primarily operates in the United States, expanding into international markets, particularly Europe and Asia, represents a significant growth opportunity. These regions have a growing demand for advanced spinal surgery solutions. Establishing distribution networks and obtaining regulatory approvals in key international markets can unlock new revenue streams and diversify the company's customer base, potentially contributing 15-20% to overall revenue growth over the next 5 years.
- Development of Advanced Biologics: The market for spinal biologics, including bone grafts and regenerative materials, is expanding due to their ability to promote bone fusion and improve surgical outcomes. Alphatec's biologics offerings, such as Alphagraft Demineralized and Cellular Bone Matrix, can be further enhanced through research and development of novel regenerative technologies. Capturing a larger share of the biologics market, estimated at $2.8 billion, can significantly boost Alphatec's revenue and profitability.
- Integration of Artificial Intelligence (AI) and Data Analytics: Incorporating AI and data analytics into spinal surgery planning and execution can improve surgical precision and patient outcomes. Alphatec can leverage its Alpha InformatiX product platform to develop AI-powered tools that assist surgeons in preoperative planning, intraoperative navigation, and postoperative monitoring. This technological advancement can differentiate Alphatec from competitors and attract surgeons seeking cutting-edge solutions, potentially increasing market share by 10-15% within the next 3-5 years.
What Opportunities Does ATEC Have?
- Expansion into international markets, particularly Europe and Asia.
- Development of advanced biologics and regenerative technologies.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Integration of AI and data analytics into surgical planning and execution.
What Threats Does ATEC Face?
- Intense competition from established medical device companies.
- Regulatory hurdles and compliance requirements.
- Product liability risks associated with spinal surgery devices.
- Economic downturns affecting hospital budgets and capital expenditures.
What Are ATEC's Competitive Advantages?
- Proprietary Technologies: Alphatec's SafeOp Neural InformatiX System provides a unique advantage by reducing the risk of nerve injury during spinal surgery.
- Comprehensive Product Portfolio: The company offers a wide range of spinal fixation systems, interbody implants, and biologics, providing a comprehensive solution for spinal disorders.
- Strong Distribution Network: Alphatec's network of independent distributors and direct sales representatives ensures broad market access and customer support.
- Innovation and R&D: Continuous investment in research and development allows Alphatec to develop innovative products and maintain a competitive edge.
What Does ATEC Do?
Founded in 1990 and headquartered in Carlsbad, California, Alphatec Holdings, Inc. has evolved into a prominent medical technology company focused on designing, developing, and advancing technologies for the surgical treatment of spinal disorders. The company's comprehensive portfolio includes a range of products, such as the SafeOp Neural InformatiX System, designed to mitigate the risk of intraoperative nerve injury, and the Sigma transforaminal lumbar interbody fusion pedicle-based access system, which enhances visualization of anatomical landmarks during surgery. Alphatec also offers the Invictus Spinal Fixation System, a thoracolumbar fixation system used to treat various spinal pathologies, and the Arsenal spinal fixation system, a comprehensive platform for addressing degenerative and deformity-related spinal conditions. Alphatec's product line extends to interbody implants like IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants, as well as biologics, including Cervical Structural Allograft Spacers and Alphagraft Demineralized and Cellular Bone Matrix. The company's commitment to innovation is evident in its development of minimally invasive surgical solutions and advanced imaging technologies, such as EOS imaging products. Alphatec distributes its products through a network of independent distributors and direct sales representatives across the United States, ensuring broad market access and customer support. Alphatec aims to deliver clinical value and improve patient outcomes through its comprehensive suite of spinal surgery solutions.
What Products and Services Does ATEC Offer?
- Designs and develops technologies for surgical treatment of spinal disorders.
- Offers the SafeOp Neural InformatiX System to reduce intraoperative nerve injury risks.
- Provides Sigma transforaminal lumbar interbody fusion pedicle-based access system for enhanced surgical visualization.
- Manufactures the Invictus Spinal Fixation System for treating a range of spinal pathologies.
- Offers a range of interbody implants, including IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants.
- Provides biologics such as Cervical Structural Allograft Spacers and Alphagraft Demineralized and Cellular Bone Matrix.
- Sells EOS imaging products for advanced spinal imaging.
How Does ATEC Make Money?
- Designs, develops, and manufactures spinal surgery technologies and products.
- Sells products through a network of independent distributors and direct sales representatives.
- Generates revenue from the sale of spinal fixation systems, interbody implants, and biologics.
- Invests in research and development to innovate and expand its product portfolio.
What Industry Does ATEC Operate In?
Alphatec Holdings, Inc. operates within the medical device industry, specifically focusing on spinal surgery solutions. The global spinal device market is characterized by technological advancements, increasing demand for minimally invasive procedures, and an aging population. Key trends include the adoption of robotic surgery, personalized implants, and advanced biologics. Alphatec competes with established players by offering innovative products like the SafeOp system and a comprehensive range of spinal fixation and interbody solutions. The company's focus on neural safety and surgical precision positions it to capture market share in this competitive landscape.
Who Are ATEC's Key Customers?
- Spinal surgeons who perform surgical procedures to treat spinal disorders.
- Hospitals and surgical centers that utilize spinal surgery technologies and products.
- Patients who require surgical treatment for spinal conditions.
- Independent distributors who sell and market Alphatec's products to healthcare providers.
Alphatec Holdings, Inc. Financial Trajectory
Alphatec Holdings, Inc. (ATEC) reported $192.1M in revenue for Q1 2026, a decline of 9.8% compared to the prior quarter. The company recorded a net loss of $33.9M, with diluted EPS of $-0.22. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ATEC averaged $-0.21 in diluted EPS.
Company Profile
Alphatec Holdings, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Patrick S. Miles. ATEC has traded publicly since 2006.
How Alphatec Holdings, Inc. Is Valued
Alphatec Holdings, Inc. carries a market capitalization of $1.43B, placing it in the small-cap category. Relative to its peer group, ATEC's quantitative score of 17/100 is below the peer average of 54/100.
P/E 18.0Key Financial Metrics
Return on assets is -15.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.90 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Alphatec Holdings, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.54 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Alphatec Holdings, Inc. revenue of about $882.4M for fiscal 2026, with EPS near $0.32. The estimate reflects 8 contributing analysts.
ATEC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Alphatec's future prospects, indicating that leadership believes in the company's growth.
- Community sentiment has shifted positively with increasing discussions around innovative product launches in the spinal surgery market.
- Analysts highlight the potential of Alphatec's new technology to capture market share, resonating well with investors looking for growth.
- The company's strategic partnerships have been well-received, enhancing its credibility and visibility in the medical device sector.
Bear Case
- Concerns about the competitive landscape in the spinal surgery market are growing, with new entrants potentially diluting Alphatec's market position.
- Recent social sentiment shows skepticism about the sustainability of growth, reflecting worries about reliance on a few key products.
- Insider selling has raised red flags for some investors, suggesting potential doubts about near-term performance.
- Market volatility and broader economic uncertainties may overshadow Alphatec's individual strengths, leading to cautious investor sentiment.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $192M | -$34M | -$0.22 |
| Q4 2025 | $213M | -$22M | -$0.15 |
| Q3 2025 | $197M | -$29M | -$0.19 |
| Q2 2025 | $186M | -$41M | -$0.27 |
Based on FMP financials and quantitative analysis
ATEC Latest News
No recent news available for ATEC.
ATEC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATEC.
Price Targets
Consensus target: $25.00
ATEC MoonshotScore
What does this score mean?
The MoonshotScore rates ATEC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Patrick S. Miles
CEO
Patrick S. Miles serves as the CEO of Alphatec Holdings, Inc., bringing extensive experience in the medical device industry. His background includes leadership roles at various medical technology companies, where he focused on strategic planning, product development, and commercialization. Miles has a proven track record of driving growth and innovation in the healthcare sector. His expertise spans across multiple disciplines, including sales, marketing, and operations, enabling him to effectively lead Alphatec's diverse teams and initiatives.
Track Record: Under Patrick S. Miles' leadership, Alphatec Holdings, Inc. has focused on expanding its product portfolio and enhancing its commercial capabilities. Key achievements include the development and launch of innovative spinal surgery solutions, such as the SafeOp Neural InformatiX System, and the expansion of the company's biologics offerings. Miles has also overseen strategic initiatives to improve operational efficiency and strengthen the company's distribution network.
Alphatec Holdings, Inc. Healthcare Stock: Key Questions Answered
What does Alphatec Holdings, Inc. do?
Alphatec Holdings, Inc. is a medical technology company focused on designing, developing, and marketing innovative solutions for spinal disorders. The company offers a comprehensive portfolio of products, including spinal fixation systems like the Invictus and Arsenal systems, interbody implants such as IdentiTi Porous Ti, and biologics like Alphagraft Demineralized and Cellular Bone Matrix. Alphatec's products are used by spinal surgeons to treat a range of spinal conditions, with a focus on improving surgical outcomes and reducing the risk of nerve injury through technologies like the SafeOp Neural InformatiX System.
What do analysts say about ATEC stock?
Analyst coverage of Alphatec Holdings, Inc. typically focuses on the company's growth potential within the spinal surgery market, driven by its innovative product portfolio and strategic initiatives. Key valuation metrics include revenue growth, gross margin, and operating expenses. Analysts often consider the company's ability to gain market share, manage expenses, and achieve profitability as critical factors. Consensus estimates may vary, but generally reflect expectations for continued revenue growth and improved financial performance over the next few years. Investors should conduct their own due diligence and consider their investment objectives before making any decisions.
What are the main risks for ATEC?
Alphatec Holdings, Inc. faces several risks inherent to the medical device industry. These include product liability risks associated with spinal surgery devices, which could lead to costly lawsuits and reputational damage. Regulatory risks, such as changes in FDA approval processes or compliance requirements, could also impact the company's ability to market and sell its products. Intense competition from established medical device companies poses a threat to Alphatec's market share and pricing power. Additionally, economic downturns could affect hospital budgets and capital expenditures, reducing demand for spinal surgery solutions.
What are the key factors to evaluate for ATEC?
Alphatec Holdings, Inc. (ATEC) holds an AI score of 17/100 (low). P/E: 18.0x vs the S&P 500's ~20-25x. Analysts target $25.00 (+169%). Not financial advice.
How frequently does ATEC data refresh on this page?
ATEC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATEC's recent stock price performance?
Alphatec Holdings, Inc. (ATEC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product portfolio with proprietary technologies like SafeOp. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATEC overvalued or undervalued right now?
Alphatec Holdings, Inc. (ATEC) trades at 18.0x earnings. Analysts target $25.00 (+169%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ATEC?
Before investing in Alphatec Holdings, Inc. (ATEC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided sources and may not reflect the most current developments.
- Financial data is as of the last available reporting period.